In his keynote speech at Ending Age-Related Diseases 2020, Dr. Aubrey de Grey of SENS Research Foundation discusses the current state of the rejuvenation biotechnology industry in the context of the current pandemic. He mentions the failure of Unity Biotechnology’s Phase 2 clinical trial for osteoarthritis, COVID-19 and the elderly immune system, the current popularization of rejuvenation biotechnology, XPRIZE, and the steps that are currently being taken towards a world without age-related diseases.
Write a comment: